MEDI1814 for IV injection + MEDI1814 for Subcutaneous Injection + IV Placebo + Placebo for Subcutaneous Injection
Phase 1Completed 0 watching 0 views this week💤 Quiet
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Mild-Moderate Alzheimer's Disease
Conditions
Mild-Moderate Alzheimer's Disease, Healthy Elderly
Trial Timeline
Feb 4, 2014 → Sep 15, 2016
NCT ID
NCT02036645About MEDI1814 for IV injection + MEDI1814 for Subcutaneous Injection + IV Placebo + Placebo for Subcutaneous Injection
MEDI1814 for IV injection + MEDI1814 for Subcutaneous Injection + IV Placebo + Placebo for Subcutaneous Injection is a phase 1 stage product being developed by AstraZeneca for Mild-Moderate Alzheimer's Disease. The current trial status is completed. This product is registered under clinical trial identifier NCT02036645. Target conditions include Mild-Moderate Alzheimer's Disease, Healthy Elderly.
Hype Score Breakdown
Clinical
10
Activity
5
Company
10
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02036645 | Phase 1 | Completed |